RecruitingPhase 3NCT06568172

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Studying Lymphoepithelial-like carcinoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Neil D Gross, DDS
NRG Oncology
Intervention: Biospecimen Collection(procedure)
Enrollment: 420 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2031

Study locations (30)

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
UC San Diego Health System - Encinitas, Encinitas, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
City of Hope Antelope Valley, Lancaster, California, United States
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
Kaiser Permanente-Oakland, Oakland, California, United States
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06568172 on ClinicalTrials.gov

Other trials for Lymphoepithelial-like carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoepithelial-like carcinoma →

← Back to all trials